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Abstract (75 word limit) 26
Vulvovaginal candidiasis (VVC) is a global health problem affecting ~75% of 27 women at least once in their lifetime. Here we examined the epidemiology of 28 VVC from a patient cohort to identify the causative organisms associated with 29 VVC. Biofilm forming capacity and antifungal sensitivity profiles were also 30 assessed. We report a shifting prevalence of Candida species with 31 heterogeneous biofilm forming capacity, both of which are associated with 32 altered antifungal drug sensitivity. 33
Fungal infections play a surprisingly substantial, yet unrecognised, health 34 burden on the global population (1). Vulvovaginal candidiasis (VVC) is one 35 example of these, where it is estimated to be the most common fungal infection 36 in a number of countries worldwide (2-4). Approximately 138 million women 37 worldwide complain of >4 episodes of VVC per year due to treatment failure, 38 clinically defined as recurrent VVC (RVVC) (5-7). These unresolved infections 39 not only have a high impact on the quality of life of these women, but can also 40 lead to further health complications (8). Candida albicans is historically 41 reported as the predominant organism isolated from VVC, accounting for over 42 90% of infections (9, 10). However, evidence of a dynamic shift in yeast 43 epidemiology has been demonstrated through an increasing prevalence of 44 non-C. albicans species (NCAS), which accounts for 11-80% of infections, 45 depending on geographical location (11). Nevertheless, C. albicans, a well-46 characterised biofilm-forming organism, remains a prominent pathogen in this 47 disease. Resistance to antifungal therapy as a result of biofilm formation is a 48 likely contributor to failed treatment. While it is widely accepted that biofilms 49 contribute to the pathogenesis of bacterial vaginosis (BV) (12, 13), their role in 50 VVC remains contested despite the overwhelming evidence to suggest 51 otherwise (14-16). To determine the biofilm forming capability of these isolates, all VVC strains 69 (n=300) were standardised to 1 × 10 6 cells/mL in RPMI-1640 and grown as 70 biofilms in 96 well plates for 24 h. Biofilms were washed with PBS and biomass 71 assessed using the crystal violet (cv) assay (18). Here we have shown that 72 vaginal isolates were able to form differential biofilms, regardless of species 73 ( Figure 2 ). C. albicans displayed the greatest heterogeneity with regards to 74 biofilm biomass, with isolates ranging from OD570nm 0.008 to 1.478, with a 75 mean of 0.416. The second most prevalent species, C. glabrata, had 76 significantly lower biomass than C. albicans (p<0.05) and C. dubliniensis 77 (p<0.01), with a mean OD570nm 0.271. This apparent biofilm heterogeneity may 78 contribute to the management of VVC infections, as these communities are 79 known to be notoriously recalcitrant to antifungal therapy, and biofilm 80 heterogeneity has been shown to correlate with in vitro antifungal therapy (18). 81
Planktonic and biofilm antifungal susceptibility testing was carried out as 82 described previously to determine the minimum inhibitory concentrations 83 (MICs) (19). Briefly, cells were standardised in RPMI-1640 before being treated 84 with fluconazole (FLZ) (Sigma, Dorset, UK) for 24 h, at a range of 85 concentrations (0.0625 to 32 mg/L). Planktonic MIC's (pMIC) were determined 86 as the lowest concentration able to completely inhibit growth visually. Sessile 87 MIC's (sMIC) were performed on 24 h preformed biofilms, with sMIC recorded 88 at 50% inhibition using an XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-89 tetrazolium-5-caboxanilide) metabolic reduction assay (20). Here we have 90
shown FLZ, the first line antifungal used to treat VVC, was ineffective against 91 most isolates, with planktonic MIC's ranging from <0.0625 to >32 mg/L ( Table  92 1). Specifically, the pMIC50 for FLZ was 4 mg/L, for C. albicans, C. glabrata and 93 C. dubliniensis, though for biofilms this was >32 mg/L. When planktonic cells 94 were stratified based on C. albicans and NCAS it was shown that 41% and 95 26% of the isolates were insensitive to FLZ at >32 mg/L, respectively. Whereas 96 for sessile cells, this rose to 51% and 56% of the isolates, respectively. 97
Interestingly, similar susceptibility profiles were observed for C. albicans and C. 98 glabrata, despite C. glabrata known to be a low biofilm former (21). This 99 reduced sensitivity in C. glabrata can be associated with its intrinsic resistance 100 to fluconazole, due to the overexpression of multidrug transporters (22). 101
VVC is not a reportable disease, making epidemiological studies difficult. 102
However, this study provides a snapshot of the species identified within a VVC 103 population, demonstrating that NCAS are responsible for an increasing number 104 of these infections. This corresponds with previous studies reporting an on-105 going dynamic shift in yeast epidemiology (23, 24), potentially driven by 106 inappropriate use of over-the-counter azoles (10). Irrespective, C. albicans 107 remained the most dominant species in this study, which questions why a high 108 number of isolates displayed reduced susceptibility to FLZ. We demonstrated 109 the ability of these clinical isolates to form heterogeneous biofilms, and the 110 presence of these communities in VVC may explain why C. albicans infections 111 remain unresponsive to FLZ therapy; an antifungal highly ineffective against C. 112 albicans biofilms (25). We cannot discount the potential for heteroresistance 113 phenotypes within these populations (26). The contribution of biofilms to VVC 114 pathogenesis remains poorly understood, though many researchers are 115 beginning to consider them important determinants of disease (14, 15), further 116 emphasising the need for research in this field. Collectively, the data from this 117 investigation highlights the necessity for careful consideration of the causative 118 organism in VVC, the biofilm phenotype and its accentuated antifungal 119 sensitivity profiles, all of which may improve antifungal treatment in this area. 120 
